Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing.
Article in JCO precision oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors at 3 institutions in 1 country.
Petra PokornaCentral European Institute of Technology, Masaryk University, Brno, Czech Republic.ORCID 0000-0003-1037-878X
Giannoula Lakka KlementDepartment of Pediatric Oncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.ORCID 0000-0002-7479-2798
Alzbeta VasikovaDepartment of Internal Medicine-Hematology and Oncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Veronika KanderovaCLIP, Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Marta JezovaDepartment of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Kristyna NoskovaDepartment of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.ORCID 0000-0001-8955-8438
Peter MudryDepartment of Pediatric Oncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Michal KyrDepartment of Pediatric Oncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.ORCID 0000-0001-6623-8386
Tomas MertaDepartment of Pediatric Oncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Viera BajciovaDepartment of Pediatric Oncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.ORCID 0000-0002-6012-3569
Zdenka KrenovaDepartment of Pediatric Oncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Hana PalovaCentral European Institute of Technology, Masaryk University, Brno, Czech Republic.
Dalibor ValikDepartment of Laboratory Methods, Faculty of Medicine, Masaryk University, Brno, Czech Republic.ORCID 0000-0003-0922-592X
Lenka Zdrazilova DubskaDepartment of Clinical Microbiology and Immunology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.ORCID 0000-0001-6397-0993
Ondrej SlabyCentral European Institute of Technology, Masaryk University, Brno, Czech Republic.
Jaroslav SterbaDepartment of Pediatric Oncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic.ORCID 0000-0002-8482-8352
Masaryk University · CZCentral European Institute of Technology · CZCharles University · CZ
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing. · full record | OpenQuestion